Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Human Autoantibody Titers After Central Nervous System Insult

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have a severe traumatic brain injury~* Have spinal cord injury ASIA grade A, B or C~* Undergoing resection of intra-axial brain tumors~Exclusion Criteria:~* Participant who is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: None): Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
- Traumatic Brain Injury (TBI) (Type: None): Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~* At 24h from the time of CNS insult~* At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~* At 3, 6, and 12 months from the time of CNS insult~* Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~* Age~* Sex~* History of prior CNS insult~* Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~* Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~* Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores
- Spinal Cord Injury (SCI) (Type: None): Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~* At 24h from the time of CNS insult~* At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~* At 3, 6, and 12 months from the time of CNS insult~* Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~* Age~* Sex~* History of prior CNS insult~* Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~* Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~* Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients
- Intracranial Neoplasm (Type: None): Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~* At 24h from the time of CNS insult~* At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~* At 3, 6, and 12 months from the time of CNS insult~* Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~* Age~* Sex~* History of prior CNS insult~* Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~* Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~* Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval